Revolution Medicines
PublicRevolution Medicines is now publicly traded
The data on this page reflects Revolution Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Feb 18, 2020
Last Round
Convertible Debt
Apr 17, 2026
Total Funding Raised
$2.97B
Company Overview
Revolution Medicines is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers.
Sector
Biotech
AI Layer
Infrastructure
Keywords
Revolution Medicines Comparables
Compare Revolution Medicines with similar companies based on industry and business-model similarity.
No public comparables are available for Revolution Medicines. Request access to learn about comparables coverage.
Request accessRevolution Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Convertible Debt | Apr 17, 2026 | ||||
| Follow-on Offering | Apr 17, 2026 | ||||
| Corporate Funding | Jun 24, 2025 | ||||
| IPO | Feb 18, 2020 | ||||
| Series C | Jul 9, 2019 | ||||
Series B | Apr 24, 2018 |
Key People
Founding team and executive leadership
Revolution Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| The Column Group | Series C, Series A Extension, Series B |
| Deerfield Management | Series C |
| Boxer Capital | Series C |
| Guggenheim Securities | IPO |
| Cormorant Asset Management | Series C |
| Fidelity Management & Research Company | Series C |
| Royalty Pharma | Corporate Funding |
Revolution Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access